zoldonrasib

AXP000029.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Revolution Medicines
Sponsor
Revolution Medicines

Names

NameTypeSource
zoldonrasibpreferred name, INNcurator, ncit
RM-036codencit
RMC-9805codencit

Cross-references

NCI Thesaurus
C201828
Wikidata
Q131410989
FDA UNII
XJ52BWK3XE

Approvals

No regulatory approval recorded.

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 32026-08-282029-03400PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07777822Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCRecruitingPhase 32026-08-142029-10430Lung Cancer (NSCLC); Metastatic NSCLC - Non-Small Cell Lung Cancer; Metastatic Non-Squamous Non-Small Cell Lung Cancer; NSCLC; Non-Small Cell Lung Cancer NSCLC; Non-Squamous Non Small Cell Lung Cancer; Non-small Cell Lung Cancer
NCT07621718Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 32026-05-222028-12-30670PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/22026-01-302029-05370Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Metastatic Solid Tumors; NSCLC; Non-small Cell Lung Cancer (NSCLC)
NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsRecruitingPhase 1/22025-05-312027-06183Lung Cancer; MTAP Deletion; NSCLC; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; RAS Mutation; Thoracic Cancer
NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/22024-05-242028-09-301130CRC; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; PDAC; Pancreatic Ductal Adenocarcinoma
NCT06162221Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/22024-01-182027-06616KRAS G12C-mutated Solid Tumors, Lung Cancer; KRAS, NRAS, HRAS-mutated NSCLC; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; Non-Small Cell Lung Cancer, NSCLC; RAS G12D-mutated NSCLC
NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingPhase 12023-09-072026-12-31604Advanced Solid Tumors; Colorectal Cancer (CRC); Non-small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC)

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42581230Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Nature medicine2026name in abstract: zoldonrasib
PMID 40056080Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.Journal of medicinal chemistry2025cited by trial NCT06040541
PMID 40705880A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.Science (New York, N.Y.)2025cited by trial NCT06040541

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42436354CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC.The EMBO journal2026name in abstract: zoldonrasib
PMID 42612796Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology2026name in abstract: zoldonrasib
PMID 42615854Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.Future medicinal chemistry2026name in abstract: RMC-9805
PMID 42645357Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges.Current oncology (Toronto, Ont.)2026name in abstract: zoldonrasib
PMID 42663603The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?Future oncology (London, England)2026name in abstract: zoldonrasib
PMID 42667948XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.Cancer letters2026name in abstract: zoldonrasib
PMID 42678463Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Journal of gastrointestinal cancer2026name in abstract: zoldonrasib
PMID 42720810Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England)2026name in abstract: RMC-9805
PMID 42759542Targeting KRAS-Mutant Lung Cancers.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: zoldonrasib
PMID 42870846Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.Translational lung cancer research2026name in abstract: zoldonrasib
PMID 42963543KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.Journal of hematology & oncology2026name in abstract: zoldonrasib
PMID 42971499Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors.Cancer letters2026name in abstract: RMC-9805
PMID 42988458Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma.Bioanalysis2026name in title: RMC-9805
PMID 40624835Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.Cancer biology & medicine2025name in abstract: RMC-9805
PMID 40805153Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Cancers2025name in abstract: RMC-9805
PMID 41423807Targeting KRAS G12D: Advances in Inhibitor Design.Thoracic cancer2025name in abstract: RMC-9805

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R03CA304041Targeting the HER Family in KRAS Mutant Colorectal CancerUNIVERSITY OF CINCINNATIGARRETT, JOAN T.2025–2025name in abstract: RMC-9805

Notes

KRAS G12D(ON) covalent tri-complex inhibitor. NCIt also lists RM-036 (unverified elsewhere).

How to cite

zoldonrasib (AXP000029.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000029.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.